The Sankei Shimbun and JAPAN Forward recently caught up with Dr. Shinya Yamanaka, the winner of the 2012 Nobel Prize in Physiology or Medicine, to help us understand the efforts being made to combat the novel coronavirus pandemic in Japan.
Dr. Yamanaka has been appointed to a Japanese government expert panel that analyzes the effectiveness of COVID-19 countermeasures. In trying to tackle COVID-19, Yamanaka, who heads Kyoto University’s Center for iPS Cell Research and Application (CiRA), has said that he is keen to pursue action based on accurate knowledge. Looking forward, he has also stressed the importance of creating a framework capable of preparing for future diseases based on the social changes and experiences stemming from pandemics such as COVID-19.
In the interview, Dr. Yamanaka discusses social impacts, the merits of access to information online, and some of the treatments being researched. Excerpts of the interview follow.
Since the start of the 21st century, the world has experienced infections such as SARS, as well as other novel strains of influenza. However, unlike those pandemics, COVID-19 is often asymptomatic and in some cases it can result in severe pneumonia. It is a very difficult challenge, the likes of which we have never faced before.
I am not a specialist in infectious diseases or public hygiene, but the more I learn about the characteristics of COVID-19, the more I recognize the importance of long-term countermeasures. On March 13, I launched a homepage with the goal of providing accurate and potentially useful information. I search the world for information that has a clear rationale, digest it in my own way, and then introduce it on the website.
The fact that Japan has a lower number of cases and deaths compared to the U.S. and Europe, despite COVID-19’s early arrival in Japan and the absence of a strict lockdown, is gaining attention. There are numerous reasons for this trend, such as thorough follow-up by healthcare centers of people coming into close contact with infected patients, Japanese people’s strong awareness of hygiene, and cultural factors, as well as the country’s robust healthcare system. Examining these factors is crucial when considering future countermeasures.
The top priority is to develop a vaccine and treatment. Researchers across the globe must work together and strive toward achieving these goals. There is also a need to establish a solid testing framework that can identify infected people.
At CiRA, we are planning to establish iPS cells generated from people infected with COVID-19 showing a variety of symptoms. Such a sample might help us understand the reasons why symptoms differ among people. iPS cells can be used to create cells infected with COVID-19 involving lung, heart, kidney, and vascular cells. We want to contribute toward the treatment of COVID-19.
Currently, society is changing drastically as a result of COVID-19. Work reforms — such as working from home, online lessons, online conferences, online medical examinations, and online sharing of patient information within medical institutions — are all taking place. We need to use these experiences and carry through any favorable changes to create a society that can react well to any future infection-related crises.
There are three ways to curb the spread of infection: reduce people-to-people contact across the nation, quickly identify infected people and then isolate them, and develop a vaccine.
However, controlling the movement of the entire country is detrimental to the economy. Also, it will take time to develop a vaccine. The second key method, identifying and isolating infected people, has so far been made possible by the noble efforts of healthcare workers.
Looking ahead, it will be crucial to have efficient identification of people who come into close contact with the infection by using an app, and to conduct PCR or antigen testing on people who have been exposed to the virus in a timely manner.
Looking ahead, it will be important to “coexist with COVID-19.”
In addition to identifying and isolating infected people, it will be necessary for the population to stay disciplined and smart about the way they do things. Across society, changes that should have taken years are happening in just a matter of months.
There is no denying that COVID-19 countermeasures will be long-term ones, but after darkness there always comes light. Eventually it will all come together again.
I think that as we undergo dramatic social changes, we should focus on the positive developments and then carry them through to the post-corona era.
2012年にノーベル医学・生理学賞を受賞した京都大iPS細胞研究所長(教授)の山中伸弥氏は、新型コロナウイルスへの対策の効果などを分析する政府の有識者会議の委員に任命された。山中氏は正しい知識に基づく行動を求める一方、パンデミック(世界的大流行)を契機とした社会の変化や経験を教訓に、次なる感染症に備えるための体制を築く必要性を強調している。
今世紀に入り、人類は重症急性呼吸器症候群(SARS)や新型インフルエンザといった感染症を経験してきた。新型コロナは、これらの感染症と比べて無症状の感染者が多い半面、一部の方では重篤な肺炎を引き起こすことから、これまでにない難敵だと感じている。
私は感染症や公衆衛生の専門家ではないが、新型コロナの特性を知れば知るほど、長期の対策が必要と考えた。3月13日にHPを開設し、正しい情報、役に立ちそうな情報を届けたいと思い、世界中から根拠が明確な情報を探して私なりに消化し、紹介している。
日本はウイルスが入ってきた時期が早く、かつ外出自粛の程度が緩やかであるにもかかわらず、欧米諸国に比べて感染者数や死者数が少ないことが注目されている。保健所を中心に濃厚接触者の追跡を徹底的に行ったこと▽日本人の衛生意識や文化的背景▽医療制度の充実-など複数の原因があると思う。この要因が何なのかを解明することが、今後の対策を考える上での鍵になる。
第一に力を注ぐべきは、ワクチンや治療薬の開発だ。世界の研究者が協力し全力で取り組まなければならない。感染者を判定する検査体制を充実させる必要もある。私たちも感染してさまざまな症状を示した方からのiPS細胞(人工多能性幹細胞)樹立を計画している。人によって症状が異なる原因の解明に貢献できるかもしれない。iPS細胞は肺、心臓、腎臓、血管細胞など、新型コロナが感染する細胞を作り出すことができ、治療法の開発に少しでも貢献したい。
現在、新型コロナの影響によって社会が大きく変化している。リモートワークを採用した働き方改革、オンラインでの授業、会議、そして診療、さらには医療機関での患者情報の共有などが進んでいる。この経験を通して、良い変化は収束後も引き継ぎ、新たな感染症の危機に立ち向かえる社会を作っていく必要がある。
感染の拡大を抑えるには、国民全体で人と人の接触を減らす▽感染者を早期に発見し隔離する▽ワクチン-の3つの方法がある。国民全体の行動制限は、経済に対する影響が甚大だ。ワクチン開発には時間がかかる。鍵となるのは2番目の感染者の判定と隔離で、これまでは保健所職員らによる献身的な努力で行ってきた。これからは、アプリなどを用いた濃厚接触者の効率的な判定、そして必要な人に速やかにPCRや抗原検査を行う体制の確立が重要だ。
これからは『新型コロナといかに共存するか』が重要。感染者の判定と隔離に力を入れるとともに、国民全員が賢い行動を粘り強く続ける必要がある。社会のいろいろな所で、数年かかると思われた変化が数カ月で起こっている。新型コロナへの対策が長期になるのは間違いないが、明けない夜はない。いつかは必ず収束する。劇的に起こった社会変化のうち、良いものに関してはポストコロナの段階でもぜひとも継続できたらと思う。